Allogeneic bone marrow transplantation for chronic myeloid leukemia. A single center experience

Archives of Medical Research

Volumn 31, Issue 2, 2000, Pages 206-209

  Vela Ojeda, Jorge ^a   Tripp Villanueva, Francisco ^a   Sánchez Cortés, Evelia ^a   Ayala Sánchez, Manuel ^a   Rosas Cabral, Alejandro ^a   Esparza, Miriam Garcı́a Ruı́z ^a   Garcı́a Chávez, Jaime ^a   Garcı́a León, Luis David ^a   González Llaven, José ^a  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

Author keywords

Bone marrow transplant; Bu Cy; Chronic myeloid leukemia; Graft vs. host disease

Indexed keywords

ACICLOVIR; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; INTERFERON; METHOTREXATE;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; MALE; MULTIVARIATE ANALYSIS; MYCOSIS; RECIPIENT; RELAPSE; SEROTYPING; SEX DIFFERENCE; SIBLING;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY; HUMANS; INFECTION; INFLAMMATION; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; LIFE TABLES; MALE; MEXICO; MIDDLE AGED; PHILADELPHIA CHROMOSOME; PREMEDICATION; PROPORTIONAL HAZARDS MODELS; RECURRENCE; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0034603604     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0188-4409(00)00071-0     Document Type: Article

References (20)

1. Thomas D.E., Clift R.A. Indications for marrow transplantation in chronic myelogenous leukemia. Blood. 73:1989;861.
2. Goldman J.M., Apperley J.F., Jones L.et al. Bone marrow transplant for patients with chronic myeloid leukemia. N Engl J Med. 314:1986;202.
3. Apperley J.F., Mauro F.R., Goldman J.M.et al. Bone marrow transplant for chronic myeloid leukaemia in first chronic phase. importance of a graft-versus-leukaemia effect Br J Haematol. 69:1989;239.
4. Gratwohl A., Hermans J., Apperley J.et al. Acute graft versus host disease. grade and outcome in patients with chronic myelogenous leukemia Blood. 86:1995;813.
5. Speck B., Bortin M.M., Champlin R.et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia. Lancet. 1:1984;665.
6. Bearman S.I., Appelbaum F.R., Buckner C.D.et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 6:1988;1562.
7. Storb R., Deeg H.J., Whitehead J.et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after bone marrow transplantation for leukemia. N Engl J Med. 314:1986;729.
8. Glucksberg H., Storb R., Fefer A.et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 18:1974;295.
9. Shulman H.M., Sale G.E., Lerner K.G.et al. Chronic cutaneous graft-versus-host disease in man. Am J Pathol. 91:1978;545.
10. Kaplan E.I., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457.
11. Cox D.R. Regression models and life tables (with discussion). J R Stat Soc. 34:1972;187.
12. Horowitz M.M., Rowlings P.A., Passweg J.R. Allogeneic bone marrow transplantation for CML. a report from the International Bone Marrow Transplant Registry Bone Marrow Transplant. 17(Suppl 3):1996;S5.
13. Clift R.A., Buckner C.D., Thomas D.E.et al. Marrow transplantation for chronic myeloid leukemia. a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide Blood. 84:1994;2036.
14. Clift R.A., Storb R. Marrow transplantation for CML. the Seattle experience Bone Marrow Transplant. 17(Suppl 3):1996;S1.
15. Bandini G., Belardinelli A., Rosti G.et al. Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies. Bone Marrow Transplant. 13:1994;577.
16. DeMagalhaes-Silverman M., Bloom E.J., Donnemberg A.et al. Toxicity of busulfan and cyclophosphamide (BU/CY2) in patients with hematologic malignancies. Bone Marrow Transplant. 17:1996;329.
17. Bross D.S., Tutschka P.J., Farmer E.R.et al. Predictive factors for acute graft-versus-host disease in patients transplanted with HLA-identical bone marrow. Blood. 63(6):1984;1265.
18. Jauntunen E., Ruutu P., Niskanen L.et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant. 19:1997;801.
19. Gratwohl A., Hermans J., Niederwieser D.et al. Bone marrow transplantation for chronic myeloid leukemia. long-term results Bone Marrow Transplant. 12:1993;509.
20. Beatty P.G. Results of allogeneic bone marrow transplantation with unrelated or mismatched donors. Semin Oncol. 19(Suppl 7):1992;13.